Atsena Reports LIGHTHOUSE data at ARVO - Takeaways - MDSpire

Atsena Reports LIGHTHOUSE data at ARVO

Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.

  • May 1, 2025

  • 3 min

Share

  • 1

    Atsena Therapeutics presented positive data from Part A of the LIGHTHOUSE study at the 2025 ARVO meeting.

  • 2

    ATSN-201, a gene therapy for X-linked retinoschisis, showed good safety and efficacy in a phase 1/2 clinical trial.

  • 3

    The therapy utilizes AAV.SPR to deliver gene expression in retinal photoreceptors while minimizing surgical risks.

  • 4

    Part A of the study involved 9 adult patients, with no serious adverse events related to ATSN-201 reported.

  • 5

    Enrollment is ongoing for Part B, which will include additional adults and pediatric patients for further evaluation.

Original Source(s)

Atsena Reports LIGHTHOUSE data at ARVO

  • May 1, 2025

Related Content

Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation

The Good News About AMD Prevention and Early Intervention

AMD severity is measured on a spectrum, and the sooner doctors, patients, and caregivers are aware of its presence, the sooner everyone can work together to protect against it. 

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.